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Abstract. Background: As pulmonary sarcomatoid
carcinomas (PSCs) are life-threatening tumors, an
improvement in their recognition in small-sized tumor
samples is clinically warranted. Materials and Methods:
Preoperative biopsy samples and paired surgical specimens
from 20 pleomorphic carcinomas, two pulmonary blastomas
and one carcinosarcoma (training set) were studied for
vimentin immunohistochemistry. A modified vimentin
histologic score (M-VHS) was devised by multiplying three
independently assessed parameters, i.e. the percentage of
positive cells (from 0 to 5+, by quintiles), the intensity of
immunostaining (low=1 vs. strong=2) and the distribution
pattern within the cytoplasm (partial=1 vs. diffuse=2), so
ranging from 0 to 20. Forty-eight consecutive and
independent cases of non-small cell lung carcinoma
(NSCLC), including two additional cases of PSC, were used
as control groups (validation set). Results: No differences in
M-VHS were found between biopsies and surgical specimens
of PSC, thus confirming the occurrence of stable epithelial
mesenchymal transition (EMT) and hence the specific
diagnosis of PSC. All types of PSC shared the same M-VHS.
The M-VHS of 46 conventional NSCLC was by far lower
(p<0.0001), whereas two additional cases of PSC showed the
same results as the training set. Poorly differentiated NSCLC
with marked pleomorphism but not stable EMT did not exhibit
significantly increased M-VHS values. Conclusion: M-VHS
helped in morphological analysis to render more definite
diagnoses on small biopsies of PSC.
Pulmonary sarcomatoid carcinomas (PSCs) make up a rare and
deadly family of non-small cell lung cancer (NSCLC)
encompassing pleomorphic carcinoma (PLC) (the most
frequent), spindle cell carcinoma (SpCC), giant cell carcinoma
(GCC), carcinosarcoma (CS) and pulmonary blastoma (PB).
Albeit diverse genophenotypically, they share, however, similar
clinical behavior and presentation of very aggressive tumors
with dismal prognosis and poor life expectancy (1-8). PSCs are
believed to derive from common protoepithelial stem cells
undergoing stable epithelial mesenchymal transition (EMT)
until complete mesenchymal phenotype “switch off” (2, 3, 6,
7, 9-11). Vimentin, a major component of intermediate
filaments in mesenchymal cells, seems to play a role of central
hub in inducing stable EMT during normal ontogenesis and
tumor development (12). The sensitivity of PSC to current
medical manipulation with platinum-based doublets, sarcoma-
specific regimes, and radiotherapy has been completely
disappointing (13-16), so it is clinically warranted to devise
more effective and simple diagnostic tools for use upon small
biopsy samples, as these tumors are presented most often at an
advanced stage, where the limited availability of tumor tissue
for diagnosis is almost the rule.
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Although it has been widely established that assessing
PSC is primarily a light microscopy exercise upon surgical
specimens (1, 3), the identification of surrogates or adjuncts
to morphology that are common to the diverse members of
this heterogeneous tumor family could help identify them in
demanding cases, especially when taking into account that
striking pleomorphism with spindling or giant cell changes
may also be shared by conventional poorly differentiated
NSCLC (3, 17). In this regard, we have recently proposed,
on a small series of PSC biopsies, that strong and diffuse
immunoreactivity for vimentin, closely paralleled the
eventual diagnoses of PSC on surgical specimens (18), but
further investigation on a wider tumor series was thought to
be necessary to solidify and generalize these preliminary
data. The hope is that better identification of PSC may lead
to substantial improvements in the treatment strategy for
these life-threatening tumors and favor the performance of
PSC-centered clinical trials, which have been thus far largely
hampered by the rarity of these tumors and the trouble in
their diagnostic recognition, too often assigned to the more
generic NSCLC category especially when faced with small-
sized diagnostic material (1, 3).
By means of a simple and reproducible immunohisto-
chemical (IHC) approach, our study indicated that a
modified-vimentin histological score (M-VHS) was a
reasonable diagnostic adjunct to morphology for rendering
more reliable diagnoses of PSC on small-sized biopsies.
These findings may be relevant to the clinical practice and
the design of specific clinical trials.
Materials and Methods
Patients and tumors. A series of 23 consecutive biopsies and
corresponding surgical specimens of PSC from 20 males (range 38-
87 years) and three females (range 30-62 years) were identified in
the pathology archives of the participant Institutions. The need for
pairing biopsy samples and surgical specimens for every patient
accounted for the relatively small number of PSCs, which are rare
tumors most often not amenable to surgery. The lack of a previous
history of cancer elsewhere in the body and the availability of
complete clinical information were also requirements for entering
the study. Pertinent clinicopathological data regarding the 23 PSCs
are presented in Table I. Small tissue fragments comprised 16
transcutaneous core biopsies, three bronchial/transbronchial
biopsies, three mediastinoscopy biopsies and one video-assisted
thoracic surgery-based biopsy, with the corresponding surgical
specimens consisting of 13 (bi)lobectomies, nine pneumonectomies
and one atypical resection. According to the 7th edition of the TNM
staging system, there were one tumor staged IA, four IB, three IIA,
eight IIB, six IIIA (four yIIIA), and one yIIIB.
All biopsies and surgical specimens had been fixed in 4% to 10%
buffered formaldehyde solution for 12-24 hours and embedded in
paraffin according to standard histopathological methods. All the
original hematoxylin and eosin (H&E)-stained sections of both
biopsies and surgical specimens were blindly reviewed without
knowledge of the patients’ identities or original tumor
categorization, according to the current lung cancer classification
(1), assuming that revision of surgical specimens made-up the gold
standard for any comparison. The study comprised of 20 PLC, two
PB and one CS when addressing surgical specimens, whereas the
diagnosis of PLC or CS was necessarily a descriptive one when
reviewing biopsies according to the diverse tumor cell components,
either conventional NSCLC or spindle and/or giant cells,
independent of their relative amount. The diagnosis of PB was
instead allowed on biopsy provided that a fetal type adenocarcinoma
was mingled with mesenchymal stroma featuring primitive blastema
(1, 7). Regarding grading, all tumors were considered poorly
differentiated by definition. Details on conventional chemotherapy
protocols or driver mutation analysis were beyond the scope of this
study dealing with the discovery and validation of a novel diagnostic
tool for PSC. Forty-six consecutive and independent surgical cases
of NSCLC and two additional cases of PSC, either biopsies or
surgical specimens, were used for validating results as negative and
positive cancer control groups, respectively.
Immunohistochemical (IHC) evaluation. The list of the antibodies
used in the current investigation and the basic technical
specifications are summarized in Table II. All tumor samples,
whether biopsy or surgical specimen, were assessed for vimentin,
an indicator of EMT in the lung (4, 18); p40 and p63, two markers
of squamous cell differentiation with the remarkable difference that
only p40 is consistently negative in lung adenocarcinoma (19-21);
thyroid transcription factor-1 (TTF1) and cytokeratin 7 (CK7), two
markers of lung adenocarcinoma; and cytokeratins 5/6 (CK5/6), a
further marker of squamous cell carcinoma (19, 22-24). In surgical
specimens, the epithelial and mesenchymal components were kept
separate while assessing the relevant antibodies, whereas in biopsies
tumor cells were evaluated as a whole without trying to distinguish
different components, if any.
Briefly, 3- to 4-μm thick sections were made to react with the
relevant antibodies and then incubated with a commercially
available detection kit (EnVision™ FLEX+; Dako, Glostrup,
Denmark) following the manufacturer’s instructions according to
previously refined IHC methods (18, 19). For all the relevant
antibodies, IHC results were rendered semiquantitatively on a scale
from 0 to 5+, taking into account the entire tumor area on paraffin
block samples and the cellular compartmentalization (nuclear area
for TTF1, p40 and p63; cytoplasmic domain for CK5/6, CK7, and
vimentin). Tumors were considered negative (0) if staining was
completely absent from the relevant cells; 1+ cases exhibited
immunoreactivity in up to 10% neoplastic cells, 2+ cases in 11-25%
neoplastic cells, 3+ cases in 26-50% neoplastic cells, 4+ cases in
51-75% neoplastic cells and 5+ cases in 76-100% neoplastic cells.
This choice was determined by the need for minimizing variability
in the slide assessment when trying precise percentages. 
In order to devise a modified vimentin histological score (M-
VHS), additional characteristics were also recorded, i.e. the
immunostaining intensity [dichotomized as low=1, if fainter than
that seen in the internal control represented by normal mesenchymal
cells (fibroblasts, lymphocytes or endothelium) vs. strong=2, if as
intense as these normal mesenchymal cells] and the distribution
pattern (dichotomized as partial=1, if limited to part of the
cytoplasm with variably reticular to membranous quality vs.
diffuse=2, if diffusely distributed to occupy the entire cytoplasmic
area). Taking into account these three independently assessed
parameters, an M-VHS was then obtained by multiplying all these,
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thus resulting in a final score ranging from 0 to 20 (i.e., maximum
value resulting from 5×2×2).
Statistical analysis. Qualitative data were compared by the Fisher’s
exact probability test and the chi-square test as appropriate.
Different M-VHS values were contrasted by the nonparametric
Mann-Whitney test. For all tests, two-sided p-values were taken into
account, with a threshold of <0.05 being statistically significant.
Results
The 23 PSCs had originally been diagnosed as sarcomatoid
carcinoma in eight cases, NSCLC-NOS in six, squamous cell
carcinoma in four, adenocarcinoma in three, suspected PB in
one and teratoma in another one (Table I). Upon revision, a
diagnosis of sarcomatoid carcinoma was reasonable in 17/23
(74%) biopsies by morphology alone, whereas in the
remaining six tumors, a definitive diagnosis of squamous cell
carcinoma and adenocarcinoma was rendered in four and two
cases, respectively. However, the small size of the diagnostic
material, the presence of variable necrosis with regressive
changes, tissue fragmentation and crush artifacts made easy
diagnostic recognition challenging and subjective for most
tumors. Moreover, among the 46 cases of conventional
NSCLC used as a negative control group, there were poorly
differentiated tumors exhibiting marked pleomorphism with
spindling and/or giant cell changes as seen in biopsy samples
of PSC.
In PSC samples, the mean M-VHS appeared to be
marginally lower in biopsies (mean value=14.7, range=0-20)
than in the sarcoma/sarcoma-like component (mean
value=19.6, range 10-20) of the relevant surgical specimens
(p=0.118). This marginal difference, however, disappeared
completely once the six tumors containing only conventional
NSCLC elements in biopsy were eliminated [mean
value=19.7 (range=16-20) vs. 19.4 (range 10-20),
respectively, p=0.984]. Differences were striking when
comparing all biopsies with the epithelial elements of the
relevant surgical specimens [mean value=14.7, (range=0-20)
vs. 2.0 (range=0-8), respectively, p=0.0001). 
Representative features of vimentin IHC in PSC and
NSCLC according to the criteria of M-VHS are depicted in
Figure 1. The 46 surgical specimens of NSCLC used as
independent negative controls for validating M-VHS
(validation set) showed that 16 (35%) cases were actually
positive for vimentin, including 7/24 squamous cell
carcinomas, 8/20 adenocarcinomas and 1/2 adenosquamous
carcinomas. However, the mean M-VHS was 4.1 (range 1-8)
in these tumors in comparison with 19.6 (range 10-20) for
PSC (p<0.0001). It emerged that PSC and conventional
NSCLC differed significantly in all the parameters under
evaluation, i.e. the percentage of vimentin-immunoreactive
cells (exclusively 5+ in PSC vs. 1+ to 5+ in NSCLC), the
intensity of immunostaining (almost always strong in PSC vs.
low in NSCLC), and the staining pattern of the cytoplasm
(always diffuse in the cytoplasm in PSC vs. reticular to
membranous in NSCLC) (Table III). Interestingly, M-VHS of
conventional NSCLC was double the corresponding value of
the epithelial component in PSC [4.1 (range=1-8) vs. 2.05
ANTICANCER RESEARCH 32: 1463-1474 (2012)
1466
Table II. Antibody panel used in the current study.
Antibody Mono (m) Clone Source Incubation Dilution Pretreatment
polyclonal (p) time
Vimentin m V9 DAKO, Glostrup, Denmark 30’ 1:50 PTLink-EDTA for 15’
p40 p - Calbiochem, Darmstadt, Germany 30’ 1:3000 PTLink-EDTA for 30’
p63 m 4A4 DAKO, Glostrup, Denmark 30’ 1:200 PTLink-EDTA for 15’
Cytokeratins 5/6 m D5/16 B4 Invitrogen, Camarillo, CA 30’ 1:25 PTLink-EDTA for 30’
Cytokeratin 7 m K 72.7 NeoMarkers, Fremont, CA 30’ 1:400 PTLink-EDTA for 15’
Thyroid transcription factor-1 m 8G7G3/1 DAKO, Glostrup, Denmark 30’ 1:2000 PTLink-EDTA for 30’
Pretreatment: Pt Link (Target Retrieval Solution, High pH-EDTA pH-8) from DAKO.
Table III. Differences in vimentin immunoreactivity.
















PSC: Pulmonary sarcomatoid carcinoma; NSCLC: non-small cell lung
cancer.
(range 0-8), respectively, p=0.008]. There were no statistically
significant differences in M-VHS among different histologies
of NSCLC (squamous cell carcinoma, adenocarcinoma and
adenosquamous carcinoma, p=0.960). Poorly differentiated
NSCLC simulating PSC in regard to spindling and/or giant
cell changes did not present with significant vimentin
immunoreactivity (Figure 2). Of note, the two additional cases
of PSC used as the positive control group in the validation set,
exhibited the same high M-VHS value in both biopsy and
surgical specimens as seen in the training set.
No differences in the distribution of semiquantitative
scores were found between biopsies and sarcoma-like
Pelosi et al: Vimentin in Pulmonary Sarcomatoid Carcinoma Biopsy Samples
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Table IV. Distribution of the relevant immunohistochemical markers in biopsy and surgical specimen.
Marker under evaluation Pleomorphic carcinoma (n=20)* 
IHC score Positivity score Biopsy Sarc-SS Epith-SS** p-Value1 p-Value2 
Cytokeratin 7 Negative 0 10 9 4 0.136 0.038
≤10% 1+ 1 0 1
11-25% 2+ 1 4 1
26-50% 3+ 3 2 1
51-75% 4+ 1 2 0
76-100% 5+ 4 3 10
Tyroid transcription factor-1 Negative 0 17 16 11 0.999 0.307
≤10% 1+ 0 1 2
11-25% 2+ 1 2 0
26-50% 3+ 1 1 2
51-75% 4+ 1 0 0
76-100% 5+ 0 0 2
Cytokeratins 5/6 Negative 0 15 19 8 0.047 0.0002
≤10% 1+ 0 0 3
11-25% 2+ 0 0 0
26-50% 3+ 2 0 3
51-75% 4+ 0 1 0
76-100% 5+ 3 0 3
p63 Negative 0 11 14 9 0.439 0.063
≤ 10% 1+ 2 0 1
11-25% 2+ 2 4 0
26-50% 3+ 0 0 1
51-75% 4+ 2 1 2
76-100% 5+ 3 1 4
p40 Negative 0 14 16 12 0.606 0.068
≤10% 1+ 1 0 0
11-25% 2+ 1 2 0
26-50% 3+ 0 0 0
51-75% 4+ 2 2 1
76-100% 5+ 2 0 4
Vimentin# Negative 0 0 0 9 0.412 6.30E-11
≤10% 1+ 0 0 1
11-25% 2+ 0 0 4
26-50% 3+ 0 0 2
51-75% 4+ 1 0 1
76-100% 5+ 13 20 0
IHC: Immunohistochemistry; *carcinosarcoma and pulmonary blastoma were excluded because of their small number; **three pleomorphic
carcinomas were composed exclusively of spindle and giant cells with no overt epithelial component; Epith-SS: epithelial components in surgical
specimens; Sarc-SS: sarcoma-like components in surgical specimens; # the six biopsies containing only epithelial components (four squamous cell
carcinomas and two adenocarcinomas), which were negative (4 cases), 1+ (1 case) or 2+ (1 case) for vimentin, were excluded from computation.
1Comparing biopsy with sarc-SS; 2Comparing sarc-SS with epith-SS.
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Figure 1. A pleomorphic carcinoma composed of spindle and giant cell carcinoma, as seen in a hematoxylin and eosin-stained section (A), exhibited
an impressively high modified-vimentin histological score (M-VHS) (B). Pulmonary blastoma with fetal type adenocarcinoma and primitive looking-
appearing stroma (inset) (C) reacted strongly and diffusely for vimentin in the mesenchymal component whereas the glandular structures were
consistently negative (D). A case of carcinosarcoma composed of adenosquamous carcinoma and sarcoma component with focal osteosarcomatous
differentiation (E, inset) exhibited a high M-VHS in the latter component, whose pattern decidedly contrasted with the almost complete negativity
for vimentin of its epithelial component (F). Exemplification of vimentin-expressing conventional adenocarcinoma (G) and squamous cell carcinoma
(H): many tumor cells actually reacted for vimentin, but their resulting M-VHS values remained negligible because of the faint immunostaining
level and the partial quality of the cytoplasmis expression (G and H) (all microphotographs are taken at ×200 magnification).
Pelosi et al: Vimentin in Pulmonary Sarcomatoid Carcinoma Biopsy Samples
1469
Figure 2. Two examples of adenocarcinoma showing marked pleomorphism in the form of giant cell changes (A) and spindle cells (C), but not
vimentin accumulation (B), and with low vimentin content (D) to denote the lack of stable epithelial mesenchymal transition. TTF1 was positive in
the spindled tumor cells, confirming adenocarcinoma diagnosis (panel C, inset). All microphotographs are taken at ×200 magnification.
Figure 3. Diagnostic algorithm constructed according to the different values of modified-vimentin histological score (M-VHSI for splitting lung cancer
into PSC (M-VHS≥10) and conventional NSCLC (M-VHS<10), in turn further classified according to the addition of p40 and the thyroid transcription
factor-1 (TTF1) immunostaining. In particular, adenocarcinoma (AD) in conventional NSCLC and AD lineage in PSC were identified by p40 negativity
regardless of TTF1, squamous cell carcinoma (SQC) in conventional NSCLC and SQC lineage in PSC by p40+/TTF1- profile, with p40>50% tumor cells
and adenosquamous cell carcinoma (ADSQC) in conventional NSCLC and ADSQC lineage in PSC by p40+/TTF+ or TTF1–/p40+, the latter with
p40<50% tumor cells). PSC with p40+/TTF1– profile could comprise tumor cells with basal-type properties heralded by progenitor/stem cells. Other
diagnostic possibilities regarding sarcoma, melanoma, mesothelioma or anaplastic/large cell lymphoma for tumors featuring M-VHS values>10 have
not been included in the diagnostic algorithm but could be reliably ruled out by means of accurate clinicopathological work-up.
elements on surgical specimens for all the remaining
markers, except CK5/6 (four PLCs had only squamous cell
carcinoma component in the relevant biopsies) (Table IV).
Significant down-regulation of epithelial markers (CK7 and
CK5/6), marginal decrease of p40/p63 and marked increase
of the number of vimentin-immunoreactive cells (a
component of M-VHS) were seen when moving from
epithelial to sarcoma-like elements (Table IV). In particular,
immunoreactivity for p40 closely correlated with the
squamous cell carcinoma component (cases IEO-2, IEO-5,
RE-02, RE-04) if 50% or more (4+ to 5+) tumor cells were
positive, and with squamous morulae in PB (case JPN-1) or
adenosquamous carcinoma in CS (case JPN-3) if up to 25%
(2+) tumor cells were positive. Three PLCs, however, devoid
of overt squamous differentiation (cases INT-04, RE-03 and
RE-05) and lacking CK5/6 surprisingly exhibited scores of
2+ to 5+ for p40 or p63 in the sarcoma-like cells only.
Unlike p40, p63 expression was retained (1+ to 4+
immunostaining) in the adenocarcinoma component of three
PLC (cases INT-2, IEO-4 and MO-02).
A practical diagnostic algorithm was then constructed in
order to differentiate the diverse subsets of conventional
NSCLC and to highlight the diverse differentiation lineages
of PSC according to the values of M-VHS and IHC for p40
and TTF1 (Figure 3). 
Discussion
The main result of our investigation is that the M-VHS helped
to diagnose PSC in biopsy samples. As novel therapy options
for PSC, a life-threatening tumor subset for which the current
treatment is disappointing, could also stem from targeting
EMT mechanisms, an ultimate recognition of PSC is of utmost
clinical relevance especially when dealing with limited
diagnostic material; moreover, distinguishing between the
diverse histological variants could be clinically unwarranted
due to the comparable clinical behavior underlying the diverse
subtypes of PSC (3). Diagnostic criteria for PSC have been
based on surgical specimens, with a 10% cut-off being
required for classification in the event of PLC (1, 3, 25), hence
the diagnosis of PSC using small biopsy specimens has been
argued against (13, 26), albeit it may be suggested or at least
reasonably suspected on biopsy (27, 28) and cytology or
analysis of cell blocks (1, 29-31), even by morphology alone.
In this article, not only did we confirm our previous
observations on the role of vimentin as a central hub (12) in
the induction of stable EMT that is a hallmark of PSC (3, 4,
9), but we also re-appraised an old and apparently useless
marker according to a novel and more objective method of
assessment, i.e. M-VHS, to assist pathologists in diagnosing
PSC more reliably, even on small biopsy samples. On this
regard, sampling error rather than an insufficient biomarker
robustness accounted for hampering of the final recognition
of PSC in six biopsies of our tumor series, inasmuch as
vimentin accumulation is deemed to be closely related to
full-blown EMT in NSCLC in general and in this tumor type
in particular (18, 19).
Our proposal of M-VHS relied on three independently
assessed and easily evaluable parameters that were
multiplied by each other to obtain a final score, namely the
percentage of positive tumor cells, the immunostaining
intensity and the labeling pattern inside the cytoplasm, hence
the suffix modified in comparison with more traditional
scoring systems. In fact, the main novelty was the
introduction of an additional parameter, namely the labeling
pattern inside the cytoplasm, which is easily appreciable
even at low magnification and actually reflects the striking
accumulation of vimentin in tumor cells due to stable EMT-
related cytoskeleton remodeling.
These three parameters were evenly distributed at the highest
level in PSC, while only few NSCLC exhibited high values of
intensity for vimentin in a lower percentage of cells or a diffuse
pattern and a high intensity in a more limited number of tumor
cells with a resulting low M-VHS (Table III). This study
represents, to the best of our knowledge, the first attempt of
using vimentin for clinical purposes in order to obtain a
substantial improvement in the diagnostic recognition of PSC
in small biopsy specimens, especially when considering that
several other markers thus far proposed for subtyping NSCLC
(18, 24, 32) may prove to be completely negative or misleading
in these tumors probably due to the irregular distribution of
epithelial traits owed to EMT changes (18, 19). On this regard,
it is worthwhile noting that cytological appraisal of poorly
differentiated NSCLC (33), a cornerstone in lung cancer
classification (1), may also be insufficient and inconclusive
alone, when considering that spindling and/or giant cell
changes not related to vimentin-driven cytoskeleton
rearrangement, the biopsy fragmentation or crush and
shrinkage tissue artifacts may be responsible for inconsistencies
between morphology and function. Although conventional
high-grade adenocarcinomas and squamous cell carcinomas of
the lung are actually known to variably undergo EMT with
vimentin accumulation (34-36) (as also suggested in our
investigation by the double value of M-VHS in conventional
NSCLC considered as a whole compared to that of the
epithelial component of PSC), we noted that M-VHS based on
diverse aspects of vimentin IHC in tumor cells (namely,
percentage, intensity of staining and intracellular distribution)
served as a powerful adjunct to morphology to substantiate the
ultimate diagnosis of PSC in small-sized biopsies (Figure 1).
The same held true for sarcoma/sarcoma-like elements of PSC,
which could easily be distinguished from the corresponding
epithelial cell component in bi-phasic tumors on the basis of
the M-VHS value, indicating that a stable EMT was occurring
in these tumors. Our results support the notion that a strong and
diffuse vimentin expression by IHC by sarcoma-like tumor
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cells featuring spindle and/or giant cell changes would
authorize diagnosis of PSC in biopsy samples, whereas the
only morphological changes of spindle and/or giant cells
without overwhelming vimentin accumulation would be a
necessary but insufficient criterion to corroborate such an
ultimate diagnosis (Figure 2). On this regard, M-VHS was able
to identify two additional cases of PSC used as the positive
control group in the validation set, which exhibited the same
high M-VHS value in both biopsy and surgical specimens as
seen in the training set. The issue of PB was different; this
could also be reliably rendered on biopsies by morphology
alone upon concurrence of fetal adenocarcinoma and blastema-
appearing primitive stroma (7). In addition, in these cases
however, M-VHS confirmed its central role as a marker of
stable EMT, helping to diagnose these tumors more confidently
(3) (Figure 1). Interestingly, while vimentin expression closely
parallels EMT in NSCLC (34-36), poorly differentiated
neuroendocrine lung tumors, practically, never undergo
significant vimentin expression according to our criteria of M-
VHS (Pelosi G, unpublished observations), while they activate
other mechanisms of cytoskeleton rearrangement, for example
through the accumulation of actin filament-bundling proteins
such as fascin (37).
Although vimentin has low diagnostic specificity because of
its wide distribution in a variety of epithelial and non-epithelial
tumors (38), it is worth stressing that once metastases to the
lung are excluded by means of an integrated
clinicopathological work-up, most of the remaining vimentin-
positive malignancies occurring in this organ actually
correspond to PSC, inasmuch as diagnostic alternatives of
primary sarcomas, melanoma or anaplastic/large cell
lymphoma are exceedingly rare occurrences, which may be
assessed by additional IHC markers (see also Table IV),
selective molecular investigations and clinical and case history
evaluation. In turn, malignant mesothelioma, whether
epithelioid or sarcomatoid, may be a formidable mimicker of
pleura-based PSC in small biopsy samples as far as vimentin
IHC is concerned, but highly specific markers, such as claudin-
4 (39), may help distinguish them from PSC. Practically
speaking, a high M-VHS (see below) in a lung-localized tumor
should alert to the possibility of PSC until proven otherwise by
using appropriate and accurate clinicopathological work-up.
For lung tumors, it was possible to construct a diagnostic
algorithm for differentiating PSC from conventional NSCLC
on the basis of the different values of M-VHS (median cut-
off=10) and a recently released, two-hit IHC approach relying
on p40 and TTF1 (19) (Figure 3). In PSC (M-VHS≥10), p40
negativity heralded adenocarcinoma lineage regardless of
TTF1, whereas p40 positivity suggested squamous,
adenosquamous or basal-type lineage. Conventional NSCLC
(M-VHS<10) were in turn split into adenocarcinoma
(p40–/TTF1+ or p40–/TTF1–), squamous cell carcinoma
(p40+/TTF1–, with p40>50% tumor cells) or adenosquamous
cell carcinoma (p40+/TTF1+ or p40+/TTF1–, the latter with
p40<50% tumor cells). Negativity for vimentin in association
with the lack of p40 and TTF1 confidently excluded PSC (but
the same profile would exclude also melanoma, sarcoma,
lymphoma and mesothelioma), paving the way to the
possibility of being faced with uncommon pulmonary
adenocarcinoma, non-conventional lung tumor or metastasis
for which careful clinical integration is mandatory (18, 19).
Although not specifically addressed as the main endpoint
of this study but inclusive to the diagnostic algorithm
depicted in Figure 3, some considerations about the
prevalence of p40 in PSC are worthwhile. In our experience,
p40 strictly correlated with squamous cell differentiation in
PLC (squamous cell carcinoma), PB (squamous morulae)
and CS (adenosquamous carcinoma), should IHC be positive,
and with adenocarcinoma differentiation, should it be
negative according to recently proposed criteria (19). In
contrast, p63 was overtly positive (1+ to 4+) also in the
adenocarcinoma component of some PSC as previously
shown (20, 21). However, PLC with no overt squamous cell
differentiation by morphology and lack of other squamous
cell carcinoma-related markers, such as CK5/6 (18) or
desmocollin-3 (40) (data not shown), showed p40-positive
tumor cells to be confined to the sarcoma-like cell
component, suggesting a possible basal-type phenotype (41)
heralded by progenitor/stem cells also in light of the
distribution of the p40-positive elements in normal lung
tissue (19). Further investigation on a wider tumor series is
needed to confirm these preliminary findings, which could
yet have some clinical relevance to personalized treatments.
In conclusion, we proposed M-VHS here as an effective
tool to reliably distinguish PSC from other NSCLC in small
biopsy specimens and indicated the possibility for p40 to
reflect a basal-like phenotype of progenitor/stem cells
potentially suitable for targeted therapy in a subset of PSC.
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